Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb 5;399(10324):496-497.
doi: 10.1016/S0140-6736(22)00095-2. Epub 2022 Jan 21.

Boosting immunity after CoronaVac

Martina Sester  1 , Sören L Becker  2
Affiliations
Comment

Boosting immunity after CoronaVac

Martina Sester et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

MS has received grant support from Astellas Pharmaceuticals and Biotest to her institution, Saarland University, outside the area of work commented on here, and honoraria for lectures from Biotest and Novartis. SLB has received travel grants and speaker fees from Astellas Pharmaceuticals, Becton Dickinson, Novartis, Pfizer, and Shionogi outside the area of work commented on here, and participated on advisory boards of Pfizer (pertaining to ceftazidime/avibactam) and Shionogi (pertaining to cefiderocol).

Comment on

References

    1. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385:e83. - PMC - PubMed
    1. Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature. 2021 doi: 10.1038/s41586-021-04388-0. published online Dec 23. - DOI - PubMed
    1. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27:1530–1535. - PMC - PubMed
    1. Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00681-2. published online Dec 7. - DOI - PMC - PubMed
    1. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022 doi: 10.1016/S0140-6736(22)00094-0. published online Jan 21. - DOI - PMC - PubMed